Empress Therapeutics

Empress Therapeutics was founded by Flagship Pioneering in 2020 to generate medicines faster by starting with the chemistry inside the human body. The company works as an extension of discovery teams, integrating automated functional genomics, chemoproteomics, and multi-omics with causal machine learning to deliver program-defining clarity. At its core is one of the world's only industrialized Perturb-seq platforms, transforming CRISPR-based single-cell functional genomics into a high-throughput regime capable of interrogating hundreds to thousands of hypotheses in parallel, with turnaround times as short as six weeks.